Brief Overview of PERSEUS, IsKia, and CASSIOPEIA Clinical Trials

Opinion
Video

Panelists discuss how patient-specific factors like age, comorbidities, cytogenetic risk status, and personal preferences guide decisions to deviate from standard protocols, with particular attention to frailty scores and organ function when considering treatment intensity.

Video content above is prompted by the following:

  • How do you decide when to deviate from standard treatment protocols based on patient characteristics?
  • Clinical Trial Insights: Please provide a brief overview of the following trials in transplant-preferred newly diagnosed multiple myeloma:
  • PERSEUS
  • IsKia
  • CASSIOPEIA
Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
9 Experts are featured in this series.
9 Experts are featured in this series.
2 experts are featured in this series.
9 Experts are featured in this series.